MR-arterioprtography: A new technical approach for detection of liver lesions

Janine Rennert, Ernst-Michael Jung, Andreas G Schreyer, Patrick Hoffstetter, Peter Heiss, Stefan Feuerbach, Niels Zorger

AIM: To evaluate the benefit and effectiveness of MR-arterioprtography (MR-AP) to achieve the highest sensitivity for detection and evaluation of hepatocellular carcinoma (HCC).

METHODS: Twenty liver cirrhosis patients with suspected HCC were included before transarterial chemoembolization. In all patients double-enhanced Magnetic resonance imaging (MRI) was performed. A bolus of 10 ml Magnevist® was injected through a selectively placed catheter in the superior mesenteric artery and MRI of the liver was performed in arterioportographic phase. Two independent readers evaluated number, size and localization of detected lesions. Diagnostic quality was determined using a 4-point scale. Differences were analyzed for significance using a t-test. Interobserver variability was calculated.

RESULTS: In all 20 patients (100%), MR-AP was feasible. Diagnostic quality was, in all cases, between 1 and 2 for both modalities and readers. MR-AP detected significantly more lesions than double-enhanced MRI (102.5 vs 61, respectively, P < 0.0024). The inter-observer variability was 0.881 for MRI and 0.903 for MR-AP.

CONCLUSION: Our study confirmed that the MR-AP as an additional modality for detection of HCC is beneficial, as significantly more lesions were detected compared to MRI with liver-specific contrast.

INTRODUCTION

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver and often develops in patients with underlying liver cirrhosis due to excessive alcohol intake, chronic hepatitis or primary biliary cirrhosis.

In the treatment of hepatocellular carcinoma, surgical resection is considered the only potentially curative therapy. However, technical improvements in hepatic surgery have extended the indications for surgery remarkably, and also regional therapeutic procedures such as transcatheter...
arterial chemoembolization (TACE)\(^{1,3}\) and radiofrequency ablation (RFA)\(^{1,4,5}\) have proved to be very successful. A prolonged time of survival following diagnosis is noted. Therefore, the pre-operative or pre-interventional workup of patients with suspected liver malignancy is even more important, especially concerning the evaluation and characterization of focal or diffuse lesions in the cirrhotic liver. Magnetic resonance imaging (MRI) has been used to improve identification of focal hepatic masses in a cirrhotic liver.

Dynamic MRI after a bolus injection of gadopentetate dimeglumine has been accepted as a valuable method for the detection and characterization of liver tumors\(^{6-9}\). Studies have shown that superparamagnetic iron oxide-enhanced magnetic resonance imaging (SPIO-MRI) increases sensitivity\(^{10,11}\).

In order to determine the treatment of choice for HCC, studies have shown that examinations by both computed tomography angiography (CTA) and computed tomography arterioporyography (CT-AP) are indispensable because of the high sensitivity of CT-AP in detecting hepatic lesions and the capability of CTA to characterize them\(^{11,12}\). However, in contrast to its high sensitivity in detecting lesions, the specificity of CT-AP for characterizing intrahepatic lesions is low. Tumor-mimicking benign perfusion abnormalities and benign lesions (e.g. hemangiomas, arterio-venous shunts) have led to a reported incidence of false-positive lesions between 9% and 63% in primary and secondary liver lesions\(^{13,14}\).

Despite advances in CT or MRI, ultrasound (US) with or without application of contrast agents also plays a key role in the diagnostic algorithm of HCC due to its low cost, availability and non-invasiveness.

Until now, there have hardly been any studies comparing the effectiveness of MR-arterioportography (MR-AP) and contrast-enhanced MRI for diagnosis of malignant liver lesions. Thus, the purpose of this study was to combine the advantages of modern contrast-enhanced MRI with the technique of arterioporyography to achieve the highest sensitivity for diagnosis of malignant liver lesions in patients suffering from HCC.

MATERIALS AND METHODS

Patients

Approval for this study was obtained from the institutional review board in conformity with the Declaration of Helsinki. Before the procedures were conducted, written informed consent was obtained from each patient for MRI, MR-AP and angiography after the nature of the procedure was fully explained.

During the period from February 2005 to September 2007, 20 patients [18 men, 2 women, age range from 47 to 76 years (mean age, 62 years)] with symptoms suggestive of primary malignant hepatic tumors were referred to our department. As HCC is commonly associated with liver cirrhosis, all patients had deteriorated liver but a tolerable renal function, and the cardiovascular status was stable. Twelve of our 20 patients suffered from alcohol toxic liver cirrhosis. In 4 out of 20 patients the underlying disease was chronic hepatitis (2 patients with chronic hepatitis B, 2 patients with chronic hepatitis C). In 4 out of 20 patients, the fundamental disease could not be elicited. Concerning the severity of cirrhosis, 8 out of 20 patients were classified as Child Pugh score A, 7 out of 20 patients as Child Pugh score B and 5 out of 20 patients as Child Pugh score C.

The existence of malignant hepatic tumors was confirmed using multislice MRI and CT. MR-AP was performed to evaluate the tumor extent in order to suggest interventional therapy, surgery or chemotherapy.

Diagnosis of HCC was histologically confirmed in 15 out of 19 patients. In one patient (patient No. 16), existence of a malignant hepatic lesion was excluded historically following liver transplantation.

In 13 out of 20 patients the α-fetoprotein (AFP) level was elevated, ranging from 16.4-2513 ng/mL (mean 488.1 ng/mL). In 7 patients (including patient No. 16) AFP levels were within a normal range.

Imaging procedures

Angiography: Before TACE and for MR-arteriopography, the femoral common artery was punctured under local anesthesia using the Seldinger technique and a 5-French angiographic catheter (Cobra, Cook Medical, USA) was positioned in the proximal superior mesenteric artery. A diagnostic angiography was performed to visualize the portal vein and to exclude shunts which could involve contrasting via the portal vein.

MRI: MRI was performed on a 1.5-T whole-body scanner (Magnetom Sonata, Siemens Medical Solutions, Germany) equipped with a high-performance gradient (Quantum) system (maximum gradient strength, 30 mT/m; slew rate, 125 T/ms). A combination of the standard body phased-array coil with spine array coils was used for signal reception.

MR-AP standard protocol (Table 1): For MR-AP, 10 mL gadopentetate dimeglumine was injected through the catheter placed in the superior mesenteric artery at a rate of 2 mL/s with a power injector (Medrad Spectris MR Injector, USA).

MRI standard protocol (Table 2): For MRI, 0.2 mmol/kg body weight gadopentetate dimeglumine was injected intravenously at a rate of 2 mL/s with a power injector (Medrad Spectris MR Injector). T1-weighted VIBE, transversal Dynamic scans were acquired 20, 40, and 120 s after application of gadopentetate dimeglumine. T2-star-weighted Flash 2D scans and T2-weighted TSE FS scans were obtained after application of 1.4 mL Ferucarbotran (Resovist®, Bayer Schering Pharma AG, Germany).

Image analysis

In the retrospective reviewing procedure, all images of each technique were interpreted and evaluated independently by two observers with great experience in abdominal MRI.
No clinical information or patient diagnosis was given to the observers. The images from each technique were interpreted in separate sessions in a randomized sequence. In the first session, the two observers reviewed a set of images that included both unenhanced and gadopentetate dimeglumine-enhanced, as well as Resovist-enhanced, images.

In the second session, each observer reviewed a set of images (MR-AP set) that included gadopentetate dimeglumine-enhanced images after injection via the superior mesenteric artery.

For characterization of liver lesions, all images of each examination were reviewed together using all the sequences available. Each observer recorded the number of suspected lesions noted, their size, and the segmental location. Furthermore, the image quality in both modalities (MR-AP and MRI) was excellent (1-2 in MR, SD: 0.4292). In patient No. 8, a patient was excluded from the evaluation for diffuse infiltration of virtually all liver segments. The image quality in both modalities (MR-AP and MRI) was excellent (1-2 in MR-arterioportography, SD: 0.4865; 1-2 in MR, SD: 0.4292). In patient No. 8, a patient was excluded from the evaluation for diffuse infiltration of virtually all liver segments. MR-AP: MR-arterioportography; MRI: Magnetic resonance imaging.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>MR-arterioportography standard protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scans</td>
<td>Plane</td>
</tr>
<tr>
<td>Unenhanced</td>
<td></td>
</tr>
<tr>
<td>T2-weighted TRUF</td>
<td>Coronal</td>
</tr>
<tr>
<td>T2-weighted TRUF</td>
<td>Transversal</td>
</tr>
<tr>
<td>T1-weighted VIBE</td>
<td>Transversal</td>
</tr>
<tr>
<td>Enhanced</td>
<td></td>
</tr>
<tr>
<td>T1-weighted FLASH FS CE</td>
<td>Transversal</td>
</tr>
<tr>
<td>T1-weighted VIBE dynamic1</td>
<td>Transversal</td>
</tr>
</tbody>
</table>

1Dynamic scans were started immediately following application of 10 mL Gd-DTPA. MRI: Magnetic resonance imaging.

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Magnetic resonance imaging standard protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scans</td>
<td>Plane</td>
</tr>
<tr>
<td>Unenhanced</td>
<td></td>
</tr>
<tr>
<td>T1-weighted VIBE</td>
<td>Transversal</td>
</tr>
<tr>
<td>T2-star-weighted FLASH 2D</td>
<td>Transversal</td>
</tr>
<tr>
<td>T2-weighted TSE FS</td>
<td>Transversal</td>
</tr>
<tr>
<td>T1-weighted FLASH opp</td>
<td>Transversal</td>
</tr>
<tr>
<td>T1-weighted FLASH in</td>
<td>Transversal</td>
</tr>
<tr>
<td>T2-weighted HASTE</td>
<td>Transversal</td>
</tr>
<tr>
<td>T2-weighted TRUF</td>
<td>Coronal</td>
</tr>
<tr>
<td>T1-weighted VIBE</td>
<td>Transversal</td>
</tr>
<tr>
<td>Enhanced</td>
<td></td>
</tr>
<tr>
<td>T1-weighted VIBE dynamic1</td>
<td>Transversal</td>
</tr>
<tr>
<td>T1-weighted FLASH FS</td>
<td>Transversal</td>
</tr>
<tr>
<td>T1-weighted FLASH FS</td>
<td>Coronal</td>
</tr>
<tr>
<td>T2-star-weighted FLASH 2D</td>
<td>Transversal</td>
</tr>
<tr>
<td>T2-weighted TSE FS</td>
<td>Transversal</td>
</tr>
</tbody>
</table>

1Dynamic scans were started immediately following application of Gd-DTPA (0.2 mmol/kg); 2Following application of 1.4 mL Resovist.

Statistical analysis
Statistical software (SPSS, version 14, Chicago, USA) was used for statistical analysis. We evaluated the differences with regard to number of lesions found using MR-arterioportography and MRI. Furthermore, the inter-observer differences in evaluation of MR-arterioportography and double-enhanced MRI were analyzed. Paired-samples \(t\) tests and \(\chi^2\) test were used to compare. In paired-samples \(t\) tests, \(P < 0.05\) indicated a statistically significant difference.

RESULTS
Twenty patients with liver cirrhosis underwent combined MR-arterioportography and SPIO-MRI examinations. No adverse reactions were experienced by any of the patients who received Gd-DTPA and SPIO.

In all 20 patients (100%), MR-arterioportography was feasible. The image quality in both modalities (MR-AP and MRI) was excellent (1-2 in MR-arterioportography, SD: 0.4865; 1-2 in MR, SD: 0.4292). In patient No. 8, a MR-AP evaluation was not suitable due to a diffuse infiltration of virtually all liver segments, thus the patient was excluded. Altogether, 102.5 hepatic lesions were detected using MR-AP, whereas only 61 lesions could be detected using MRI (Table 3). This difference is considered to be statistically significant (\(P < 0.0024\)). The kappa analyses of two observers regarding the number of lesions detected by both modalities showed substantial to excellent agreement (\(\kappa = 0.903\), 95% CI: 0.844 to 0.962 for MR-AP; and \(\kappa = 0.881\), 95% CI: 0.795 to 0.966 for MRI). In particular, \(\kappa\) values with MR-AP imaging indicated excellent agreement.

The lesions found in all patients ranged in size from 7-120 mm (mean 28.24 mm) for MRI and from 4-120 mm (mean 24.62 mm) for MR-AP. This difference is not con-
Histology obtained following liver transplantation confirmed the diagnosis of a multifocal hepatocellular carcinoma. Therefore, the lesions were also classified as malignant. Diagnosis of HCCs was histologically confirmed in 15 out of 19 patients. In patient No. 16, one lesion was found in segment 8 of the liver which showed a portal venous enhancement with accumulation of Ferucarbotran and no traceability in MR-AP. The lesion therefore was classified as benign, i.e. regenerated nodule that was confirmed histologically following liver transplantation (Figures 1 and 2).

**Discussion**

Before decisions are made as to hepatic resection of hepatocellular carcinoma or interventional treatment such as TACE, percutaneous ethanol injection therapy and radiofrequency ablation (RFA), accurate information regarding the number and localization of lesions is essential.

Because of its high sensitivity for detecting lesions, CT-AP is one of the most reliable tools for detection of liver lesions. The rationale of CT-AP is for contrast material to be delivered directly to the liver through the portal vein before it can return to the hepatic artery from the systemic circulation, to optimize the detection of tumor lesions that do not have portal vein flow and appear as hypodense nodules. The aim of our study was to combine the advantages of arteriportal contrast and MRI to detect liver lesions in patients with HCC. MRI with liver-specific contrast agents is currently the imaging modality of choice. Most studies that have directly compared MRI with CT-AP in patients with HCC or metastases reported no significant differences in sensitivity,[15-17], but in some studies a higher specificity for MRI is reported.[13]

Preoperative or pre-interventional workup of patients with suspected liver malignancy is even more important, especially concerning the evaluation and characterization of a focal lesion or diffuse infiltration of the cirrhotic liver.

Regarding the detection of HCCs, it has been reported that ferumoxide-enhanced MR imaging is more sensitive than unenhanced MR imaging,[18,19] or contrast-enhanced CT,[20,21] and at least as accurate as CT during arterioporphorytography.[22,23] Preoperative or pre-interventional workup of patients with hepatic cirrhosis due to chronic hepatitis B and C infection. Histology obtained following liver transplantation confirmed the diagnosis of a multifocal hepatocellular carcinoma. A: Magnetic resonance imaging (T1-weighted VIBE) during early venous phase shows a low signal intensity nodule with a diameter of approximately 3 cm in segment VIII; B: SPIO-enhanced T2-weighted fast image shows an area of increased signal intensity (segment VIII) within the otherwise lower but very inhomogenous signal of the liver parenchyma with profound cirrhosis; C: MR-AP (T1-weighted VIBE) during early venous phase displays an area of decreased enhancement (approx. 4.5 cm diameter) in segment VIII. Note the multiple smaller hypointense lesions in segments VII/VI. SPIO: Superparamagnetic iron oxide-enhanced.
April 7, 2011

Histology obtained following liver transplantation confirmed the diagnosis of a well differentiated hepatocellular carcinoma. A: Magnetic resonance imaging (T1-weighted VIBE) during arterial phase shows a singular hyper-vascularized nodule with a diameter of approximately 2 cm in segment VIII; B: T1-weighted VIBE during early venous phase shows an inhomogenous signal of the liver parenchyma with masking of the lesion in segment VII; C: SPIO-enhanced T2-weighted fast image shows an area of increased signal intensity (segment VIII) within a low signal of the liver parenchyma; D: MR-AP (T1-weighted VIBE) during early venous phase displays an area of decreased enhancement (approx. 3 cm diameter) in segment VII and various low signal lesions in segments I, IVa, VIII and VII. SPIO: Superparamagnetic iron oxide-enhanced.

In summary, our study confirmed that the use of MR-arteriportography as an additional modality for detection of hepatocellular carcinoma is useful. Using this technique, significantly more lesions could be detected in comparison to MRI with liver-specific contrast agent.

COMMENTS

Background
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver and often develops in patients with underlying liver cirrhosis. In the treatment of HCC, surgical resection is considered the only potentially curative therapy; however, other regional therapeutic procedures such as transcatheter arterial embolization or radiofrequency ablation have proved to be very successful. Thus, the pre-interventional evaluation of patients with suspected liver malignancy is even more important, especially concerning the evaluation and characterization of focal or diffuse lesions in the cirrhotic liver.

Research frontiers
MR imaging with liver-specific contrast agents has been used to improve identification of focal hepatic masses in a cirrhotic liver. Also, studies have shown that examinations by computed tomography arteriportography (CT-AP) have a very high sensitivity for detection of hepatic lesions compared to a relatively low specificity. In this study, the benefit and effectiveness of MR-arteriportography (MR-AP) in achieving the highest sensitivity for detection and evaluation of HCC was evaluated.

Innovations and breakthroughs
Until now, there have hardly been any studies comparing the effectiveness of MR-AP and contrast-enhanced MRI for diagnosis of malignant liver lesions. This study confirmed that MR-arteriportography as an additional modality for detection of HCC is truly beneficial and may lead to change in treatment in many patients.

Applications
The results showed that using the MR-AP approach, significantly more lesions could be detected in comparison to MRI with liver-specific contrast agent. Thus, it might play an important role for future strategy of therapeutic interventions.

Our study demonstrated that MR-arteriportography as an alternative method for detection of HCC is not only feasible but showed a significantly larger number of lesions than ferumoxide-enhanced MR imaging, especially in patients with hepatic cirrhosis.

Also, the lesion’s size seems to play a crucial role. Out of the 41 lesions that were exclusively found using MR-AP, 21 were 10 mm or less in diameter. This confirms the high sensitivity of MR-AP, especially regarding smaller lesions. However, a definite differentiation among HCC nodules, regenerative dysplastic nodules or, for example, small arterio-venous shunts that are very common in patients with hepatic cirrhosis, is not possible.

One limitation of the study is that a histological confirmation of HCC or benign lesions could only be obtained in 16 out of 20 patients. In the other 4 patients, further treatment was based upon the combination of typical image morphology and elevated alpha fetoprotein. Another limitation is the relatively small number of patients that were examined in this study. Prospective studies are necessary in order to ascertain the diagnostic reliability of MR-AP compared to established methods.

In this study, the benefit and effectiveness of MR-arteriportography (MR-AP) in achieving the highest sensitivity for detection of HCC was evaluated.
**Terminology**

MR-AP is an MRI procedure where the contrast agent is injected through a catheter placed in the superior mesenteric artery.

**Peer review**

It is well-written and is novel work.

**REFERENCES**


S- Editor Sun H    L- Editor Logan S    E- Editor Ma WH